Moxifloxacin Stulln (Moxifloxacin)

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, the drug prevents bacterial cell division, leading to bacterial death and resolution of the infection.

The dosing regimen for Moxifloxacin Stulln is determined by the prescribing ophthalmologist based on the specific infection, severity and patient factors. The prescriber will provide detailed instructions on the number of drops, frequency and duration of therapy.

Safety data for ocular moxifloxacin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the prescriber should evaluate each case individually.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxifloxacin is a fourth‑generation fluoroquinolone offering broad‑spectrum activity against Gram‑positive and Gram‑negative ocular pathogens, often with lower resistance rates compared with older agents such as ciprofloxacin. It provides convenient once‑daily dosing for many indications, which can improve patient compliance.

Store the ophthalmic solution at room temperature below 25 °C in its original container. Protect it from moisture, direct sunlight and extreme temperatures. Keep the bottle tightly closed when not in use and discard any solution that appears discolored or contaminated.

The solution is applied topically to the affected eye(s) as directed by the prescriber. Typically, one to two drops are instilled into the conjunctival sac, avoiding contact with the eyelid or lashes. Patients should wash their hands before and after administration.

Serious adverse events, though rare, include corneal epithelial toxicity, severe allergic reactions such as contact dermatitis, and vision‑threatening inflammation. Any sudden worsening of symptoms or signs of an allergic response should prompt immediate medical evaluation.

Patients with known hypersensitivity to moxifloxacin, other fluoroquinolones, or any component of the formulation should avoid this product. Caution is also advised for individuals with a history of tendon disorders or QT‑interval prolongation when systemic exposure is possible.